Trends in Pharmacological Sciences
In vitro and pharmacophore insights into CYP3A enzymes
Section snippets
CYP3A4 complexity
Recently, it has become apparent that the kinetic interaction between CYP enzymes and their substrates in vitro is often atypical, as exemplified by CYP3A4 (Fig. 1). There are several reviews on this topic 9, 10, 11. Adding to this complexity, constituents of the incubation buffer appear to alter both the behavior of the enzyme [12] and the conformation of the active site [13]. Furthermore, chemical inhibition of catalysis by CYP3A4 is substrate dependent 5, 14, 15 and the inhibition response
Beyond in vitro
The pharmaceutical industry pays considerable attention to computational approaches that predict the absorption, distribution, metabolism, excretion and toxicology of test a molecule to eliminate failures well before precious resources are allocated for the development of the compound 25, 26, 27, 28, 29. Drug–drug interaction data can be turned into three-dimensional, visual, computational models (termed ‘pharmacophores’), that describe key features of molecules that are likely to be important
Caveats and context
It is important to note that some of the inhibitors used in this analysis (clotrimazole, erythromycin, ketoconazole and mibefradil) might not inhibit CYP3A by a strictly competitive mechanism and that we have used only a single substrate probe (BFC) in this analysis. Therefore, our pharmacophores might be limited in their representation compared to the CYP active site and it might be useful to use the present pharmacophore approach with competitive inhibitors of multiple substrate probes in
Similarities and differences
In many cases, the three CYP3A enzymes have similar catalytic characteristics in terms of substrate specificity, regiospecificity and kinetics [35]. However, for some molecules there are significant differences between the enzymes. For example, the CYP3A4 substrate cisapride is not an adequate substrate for CYP3A7 [41], whereas the 16-α hydroxylation of dehydroepiandrosterone sulfate is catalyzed preferentially by CYP3A7 [42]. Significant regiospecific differences in substrate metabolism also
Concluding remarks
Combining experimental and computational approaches to probe the molecular features necessary for substrates and inhibitors to interact with the binding domain in each CYP3A enzyme complements other studies. Future datasets of inhibitors of structurally diverse substrate probes for these enzymes might enable further definition of different regions of the active sites of CYP3A, in particular the molecular features that are required to interact with distinct binding domains of CYP3A. Ultimately,
Acknowledgements
We gratefully acknowledge Thuy Ho and Stephanie D. Turner for technical assistance, and Charles L. Crespi and Rajesh Sangar for comments and discussion.
References (45)
Design and application of fluorimetric assays for human cytochrome P450 inhibition
Methods Enzymol.
(2002)Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6 and CYP3A4 in vitro using a single point IC50
J. Biomol. Screen.
(2002)Present and future in vitro approaches for drug metabolism
J. Pharmacol. Toxicol. Methods
(2000)A kinetic model for the metabolic interaction of the two substrates at the active site of cytochrome P450 3A4
J. Biol. Chem.
(2001)- et al.
Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains
Arch. Biochem. Biophys.
(2001) Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and α-napthoflavone stimulation
Arch. Biochem. Biophys.
(1998)Drug–drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4
Biochem. Pharmacol.
(1997)- et al.
In silico ADME/TOX: the state of the art at the 220th ACS meeting
J. Mol. Graph.
(2002) Progress in predicting human ADME parameters in silico
J. Pharmacol. Toxicol. Methods
(2000)- et al.
Pharmacophore modeling of cytochromes P450
Adv. Drug Deliv. Rev.
(2002)